CURRENT PORTFOLIO |
|
|
|
|
Aeterna Zentaris |
Cetrotide® |
Traditional passive royalty |
2008 |
|
Dyax Corp. |
Phage display Licensing & Funded Research Program / Ecallantide |
Synthetic Royalty® / Equity |
2009 / 2008 |
|
Fosamprenavir Royalty, L.P. |
| acquired from Vertex Pharmaceuticals |
 |
|
Lexiva® / Telzir® |
Traditional passive royalty /
structured royalty debt |
2008 |
|
Ledgemont Royalty Sub LLC |
| affiliate of Indevus Pharmaceuticals |
|
|
Sanctura® / Sanctura XR® |
Structured royalty debt |
2008 |
|
LifeCycle Pharma |
Fenoglide® |
Traditional passive royalty |
2008 |
|
Suneva Medical |
Artefill® |
Synthetic Royalty® / Equity |
2009 / 2008 |
|
TCD Royalty Sub LLC |
| affiliate of Supernus Pharmaceuticals |
|
|
Oracea® / Santura XR® |
Structured royalty debt |
2008 |
|
|
|
|
|
|
| |
|
|
|
|
SELECTED PREVIOUS INVESTMENTS |
|
|
|
Acorda Therapeutics |
Zanaflex Capsules® |
Synthetic Royalty® |
2005 |
|
AVANT Immunotherapeutics |
| now known as Celldex Therapeutics |
|
|
Rotarix® |
Traditional passive royalty |
2005 |
|
Aventis |
| now known as sanofi-aventis |
|
|
Lunesta® |
Traditional passive royalty |
2004 |
|
Cincinnati Children's Hospital |
Rotarix® |
Traditional passive royalty |
2005 |
|
Prism Pharmaceuticals |
Nexterone® |
Synthetic Royalty® / Equity |
2006 |
|
The Wistar Institute |
RotaTeq® |
Traditional passive royalty |
2005 |
|
